Rockbridge Investment Management, Lcc Incyte Corp Transaction History

Rockbridge Investment Management, Lcc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $21,646 - $26,638	-415 Reduced 71.55%	165 $10.4 Million
Q3 2022 May 28, 2024	SELL	$66.18 - $82.86 $10,919 - $13,671	-165 Closed	0 $0
Q1 2022 May 28, 2024	BUY	$66.02 - $79.71 $10,893 - $13,152	165 New	165 $13,000
Q1 2021 May 20, 2021	BUY	$76.02 - $100.5 $1,900 - $2,512	25 Added 4.5%	580 $47,000
Q4 2020 Mar 04, 2021	BUY	$80.74 - $97.7 $4,036 - $4,885	50 Added 9.9%	555 $48,000
Q3 2020 Nov 03, 2020	BUY	$85.07 - $109.69 $35,304 - $45,521	415 Added 461.11%	505 $45,000
Q2 2020 Aug 20, 2020	BUY	$74.18 - $108.93 $6,676 - $9,803	90 New	90 $9,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Rockbridge Investment Management, Lcc, based on Form 13F filings with the SEC.

Stay updated on Rockbridge Investment Management, Lcc with notifications on news.